GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Onesource Specialty Pharma ONESOURCE.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

1,618.00

+1.14%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in INR, from our data supplier.

FY2026

Revenue

₹14.22bn

FY2023FY2026

Net income

−₹738.0m

FY2023FY2026

Free cash flow

−₹6.80bn

FY2023FY2026

Shareholders' equity

₹58.31bn

FY2023FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023
Revenue₹14.22bn₹14.45bn₹1.72bn₹387.1m
Research and development—₹20.5m——
Operating income₹251.3m₹1.90bn——
Net income−₹738.0m−₹2.1m−₹3.91bn−₹8.00bn
Diluted earnings per share-6.44-0.02-34.18-69.77

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023
Total assets₹82.10bn₹75.50bn₹13.09bn₹20.09bn
Cash and short-term investments₹1.03bn₹36.2m——
Total liabilities₹23.79bn₹209.7m₹9.13bn₹12.23bn
Debt₹15.04bn₹9.42bn₹2.72bn₹3.35bn
Shareholders' equity₹58.31bn₹58.81bn₹3.96bn₹7.85bn
Shares outstanding115m115m114m115m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023
Cash from operations−₹1.11bn−₹24.7m−₹1.07bn−₹1.63bn
Capital spending−₹5.69bn−₹1.28bn−₹637.7m−₹439.9m
Free cash flow−₹6.80bn−₹1.31bn−₹1.71bn−₹2.07bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₹4.49bn₹4.28bn₹2.90bn₹3.76bn₹3.27bn₹4.26bn₹3.93bn₹3.34bn
Operating income₹516.0m₹200.9m−₹523.2m₹366.7m₹206.8m₹1.14bn₹731.2m₹95.4m
Net income₹250.0m₹46.0m−₹887.0m₹104.8m−₹1.9m₹985.0m−₹688.5m−₹420.8m
Diluted earnings per share2.180.40-7.740.92-0.028.60-6.02-3.68
Cash from operations———−₹399.0m————
Capital spending———−₹3.29bn————
Free cash flow———−₹3.69bn————
Total assets—₹82.10bn—₹80.13bn—₹75.50bn——
Cash and short-term investments—₹1.03bn—₹1.80bn—₹3.10bn——
Debt—₹12.85bn—₹10.73bn—₹7.79bn——
Shareholders' equity—₹58.31bn—₹59.04bn—₹58.81bn——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue232.4%——
Net income-54.8%——

Valuation history

At each fiscal year end

FY2026FY2025
Price to earnings-251.5-98746.7
Price to sales13.114.4

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.